生物标志物对抗血管生成药物疗效预测作用的进展

血管生成与肿瘤的生长、浸润和转移过程密切相关，针对恶性肿瘤血管生成的治疗已经逐渐成为肿瘤治疗的重要方式。抗血管生成药物在临床上的广泛应用，给患者带来获益的同时也带来了毒副反应以及经济负担，因此有关预测抗血管生成药物疗效的标志物的研究也越来越多。有部分研究发现，血管内皮生长因子（VEGF）／血管内皮生长因子受体（VEGFR）通路相关因子、血管内皮破坏相关的循环内皮细胞、CXC趋化因子家族的细胞因子及其他血管生成调控因子可以预测抗血管生成药物的疗效，但是不同的研究得出的结论并不完全相同，相关预测因子的研究并没有获得大范围的认可。本文就生物标志物在抗血管生成药物的疗效预测作用方面做一综述。

Predictive biomarkers to antiangiogenesis therapies

The development of new blood vessels not only serves to supply the tumor tissue with nutrients， but they can also serve as a means for cancer cells to metastasize. Anti-angiogenic therapy for cancer has gradually become an important way of cancer therapy. The widespread use of anti-angiogenic drugs in clinical practice not only brings benefits to patients but also brings side effects and economic burdens. Therefore more and more researches on predictive biomarkers to anti-angiogenesis therapies have been carried out. Some studies have found that vascular endothelial growth factor（VEGF）／vascular endothelial growth factor receptor（VEGFR） pathway related factors， cytokines of CXC chemokine family and other angiogenic regulators can predict the efficacy of anti-angiogenic drugs. However， the conclusions of different studies are not exactly the same， and the related predictors are not widely accepted. This article reviews the predictive effects of biomarkers on anti-angiogenic drugs.